ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET
Company Participants
Al Kildani - SVP of IR & Corporate Communications
Catherine Owen Adams - CEO
Tom Garner - COO
Elizabeth Thompson - EVP and Head of R&D
Mark Schneyer - EVP and CFO
Conference Call Participants
Ritu Baral - TD Cowen
Tessa Romero - JPMorgan
Ash Verma - UBS
Elaine Kim - Canter
Basma Radwan - Leerink Partners
David Huang - Deutsche Bank
Tazeen Ahmad - Bank of America
Yatin Suneja - Guggenheim
Joel Beatty - Baird
Sumant Kulkarni - Canaccord Genuity
Malcolm Hoffman - BMO Capital Markets
Operator
Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Lauren Cannon, and I'll be your coordinator for today. After the speaker's presentation, there will be a question and answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to turn the presentation over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at ACADIA. Please proceed.
Al Kildani
Good afternoon, and thank you for joining us on today's call to discuss ACADIA's first quarter 2025 financial results. Joining me on the call today from ACADIA are Catherine Owen-Adams, our Chief Executive Officer, who will provide some opening remarks, followed by Tom Garner, our Chief Commercial Officer, who will discuss our strong commercial brand debut in New Plaza. Also joining us today is Elizabeth Thompson, Ph.D., Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs, and Mark Schneyer, our Chief Financial Officer, who will review the financial highlights. Catherine will then provide some closing thoughts before we open up the call for your questions.
We are using supplemental slides which are
- Read more current ACAD analysis and news
- View all earnings call transcripts